Can a new freezing balloon tame a fluttering heart as well as the old one?

NCT ID NCT04704986

First seen Jul 24, 2026 ยท Last updated Jul 24, 2026

Summary

This trial tests whether a newer cryoballoon device, PolarX, works as well as the standard Arctic Front device for treating paroxysmal atrial fibrillation (a type of irregular heartbeat). About 200 people having their first pulmonary vein isolation procedure will be randomly assigned to one of the two devices. The study will monitor heart rhythm for a year to see how well each device prevents the return of atrial fibrillation.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
a cryoballoon catheter device used to freeze and isolate pulmonary veins
What this could lead to
If the PolarX device proves as effective as the current standard, it could offer doctors another safe option for treating atrial fibrillation.
What could go wrong
This is a non-inferiority trial, so the new device may turn out to be less effective. Complications like heart lining inflammation or nerve injury are possible with any cryoballoon procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Inselspital, Bern University Hospital

    Bern, 3010, Switzerland

  • University Hospital Basel

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.